1. Safety and immunogenicity of the adjunct therapeutic vaccine ID93 + GLA-SE in adults who have completed treatment for tuberculosis: a randomised, double-blind, placebo-controlled, phase 2a trial. Issue 4 (April 2021) Authors: Day, Tracey A; Penn-Nicholson, Adam; Luabeya, Angelique Kany Kany; Fiore-Gartland, Andrew; Du Plessis, Nelita; Loxton, Andre G; Vergara, Julie; Rolf, Tom A; Reid, Tim D; Toefy, Asma; Shenje, Justin; Geldenhuys, Hendrik; Tameris, Michele; Mabwe, Simbarashe; Bilek, Nicole; Bekker, Linda-Gail; Diaco... Journal: Lancet Issue: Volume 9:Issue 4(2021) Page Start: 373 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Safety and immunogenicity of the adjunct therapeutic vaccine ID93 + GLA-SE in adults who have completed treatment for tuberculosis: a randomised, double-blind, placebo-controlled, phase 2a trial. Issue 4 (April 2021) Authors: Day, Tracey A; Penn-Nicholson, Adam; Luabeya, Angelique Kany Kany; Fiore-Gartland, Andrew; Du Plessis, Nelita; Loxton, Andre G; Vergara, Julie; Rolf, Tom A; Reid, Tim D; Toefy, Asma; Shenje, Justin; Geldenhuys, Hendrik; Tameris, Michele; Mabwe, Simbarashe; Bilek, Nicole; Bekker, Linda-Gail; Diaco... Journal: Lancet Issue: Volume 9:Issue 4(2021) Page Start: 373 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗